90276-19-0

Upstream product

• 609-67-6 2-Iodobenzoyl chloride 
• 412272-54-9 ethyl 3-(2-iodophenyl)acrylate 
• 378759-67-2 ethyl (E)-3-(2-iodophenyl)-2-propenoate 
• 15310-01-7 benodanil 
• 26260-02-6 2-iodobenzaldehyde 
• 5159-41-1 2-iodobenzyl alcohol 
• 121263-09-0 (2-iodo-benzylidene)-malonic acid 
• 7732-18-5 water 
• 141-82-2 malonic acid 
• 39993-62-9 (E)-3-(2-iodophenyl)propenal 
• 1664-63-7 2-amino-cinnamic acid 
• 615-43-0 2-iodophenylamine 
• 127-09-3 sodium acetate 

Downstream Products

• 96606-95-0 3-(2-iodophenyl)propanoic acid 
• 639785-12-9 2-iodo-cinnamoyl chloride 
• 1027219-61-9 (E)-3-(2-Iodo-phenyl)-acryloyl azide 
• 1417698-28-2 (2E)-N-(2-aminophenyl)-3-(2-iodophenyl)acrylamide 
• 1417698-30-6 tert-butyl (2-{[(2E)-3-(2-iodophenyl)prop-2-enoyl]amino}ethyl)carbamate 
• 1417698-31-7 (2E)-3-(3-hydroxy-4-methoxyphenyl)-N-(2-{[(2E)-3-(2-iodophenyl)prop-2-enoyl]amino}ethyl)-2-(3,4,5-trimethoxyphenyl)acrylamide 
• 122951-06-8 ethyl 3-(2-iodophenyl)propanoate 
• 1026955-47-4 3-bromo-3-(2-iodo-phenyl)-propionyl chloride 
• 817623-35-1 4-bromo-4-(2-iodophenyl)-1-diazo-2-butanone 
• 55170-65-5 2-Oxo-1(2H)-chinolinessigsaeure 
• 378759-67-2 ethyl (E)-3-(2-iodophenyl)-2-propenoate 
• 1025951-73-8 3-bromo-3-(2-iodo-phenyl)-propionic acid 

Relevant academic research and scientific papers

SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING A PSYCHIATRIC DISORDER

The present invention relates to a pharmaceutical composition for treating and/or alleviating a psychiatric disorder comprising a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a pharmaceutical composition for inducing anti-stress, anti-anxiety and/or anti-depressant activities comprising a sulfamate derivative compound and/or a pharmaceutically acceptable salt thereof as an active ingredient.

Synthetic Studies Toward the Skyllamycins: Total Synthesis and Generation of Simplified Analogues

Herein, we report our synthetic studies toward the skyllamycins, a highly modified class of nonribosomal peptide natural products which contain a number of interesting structural features, including the extremely rare α-OH-glycine residue. Before embarking on the synthesis of the natural products, we prepared four structurally simpler analogues. Access to both the analogues and the natural products first required the synthesis of a number of nonproteinogenic amino acids, including three β-OH amino acids that were accessed from the convenient chiral precursor Garner's aldehyde. Following the preparation of the suitably protected nonproteinogenic amino acids, the skyllamycin analogues were assembled using a solid-phase synthetic route followed by a final stage solution-phase cyclization reaction. To access the natural products (skyllamycins A-C) the synthetic route used for the analogues was modified. Specifically, linear peptide precursors containing a C-terminal amide were synthesized via solid-phase peptide synthesis. After cleavage from the resin the N-terminal serine residue was oxidatively cleaved to a glyoxyamide moiety. The target natural products, skyllamycins A-C, were successfully prepared via a final step cyclization with concomitant formation of the unusual α-OH-glycine residue. Purification and spectroscopic comparison to the authentic isolated material confirmed the identity of the synthetic natural products.

Selective Palladium-Catalyzed Domino Heck/Buchwald–Hartwig Arylations of N-Glycosylcinnamamides: An Efficient Route to 4-Aryl-N-glycosylquinolin-2-ones

An efficient and selective domino Heck/Buchwald–Hartwig arylations of readily available N-glycosylcinnamamides with aryl iodides have been established. Using palladium(II) acetate as a catalyst, potassium acetate as the base and tetrabutylamonium bromide as an additive in dioxane, the protocol proved to be general, and a variety of 4-aryl-N-glycosylquinolin-2-ones has been prepared in good yields with exclusive α- or β-selectivity. (Figure presented.).

SULFAMATE DERIVATIVE COMPOUND FOR USE IN PREVENTING OR TREATING EPILEPSY

The present invention relates to a pharmaceutical composition for treating or preventing epilepsy containing a sulfamate derivative compound and/or pharmaceutically acceptable salt thereof as an active ingredient. Furthermore, the present invention relates to a method for treatment or prevention epilepsy comprising administering a sulfamate derivative compound in a pharmaceutically effective amount to a subject in need of treatment or prevention of epilepsy.

PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME

The present invention relates to novel phenylalkyl sulfamate compounds, a method for preventing or treating a disease associated with muscle spasm. The present invention ensures the enhancement of muscle relaxation activity essential for alleviation of muscle spasm, such that it is promising for preventing or treating various diseases associated with muscle spasm.

Ring expansion-annulation strategy for the synthesis of substituted azulenes and oligoazulenes. 2. Synthesis of azulenyl halides, sulfonates, and azulenylmetal compounds and their application in transition-metal-mediated coupling reactions

A "ring expansion-annulation strategy" for the synthesis of substituted azulenes is described based on the reaction of β'-bromo- α-diazo ketones with rhodium carboxylates. The key transformation involves an intramolecular Buechner reaction followed by β-elimination of bromide, tautomerization, and in situ trapping of the resulting 1-hydroxyazulene as a carboxylate or triflate ester. Further synthetic elaboration of the azulenyl halide and sulfonate annulation products can be achieved by employing Heck, Negishi, Stille, and Suzuki coupling reactions. Reaction of the azulenyl triflate 84 with pinacolborane provides access to the azulenylboronate 91, which participates in Suzuki coupling reactions with alkenyl and aryl iodides. The application of these coupling reactions to the synthesis of biazulenes, terazulene 101, and related oligoazulenes is described, as well as the preparation of the azulenyl amino acid derivative 110.

5-Nitrofuran-2-ylmethyl group as a potential bioreductively activated pro-drug system

5-Substituted isoquinolin-1-ones have been synthesised by one-pot Curtius rearrangement of the corresponding substituted 3-phenylpropenoyl azides and cyclisation. Arylmethylation of the anions of the isoquinolinones with benzyl halides [4-methoxybenzyl chloride, 2-(chloromethyl)furan and 5-nitro-2-(tosyloxymethyl)furan] takes place exclusively at nitrogen. Nitration of 2-(furan-2-ylmethyl)isoquinolin-1-one in strongly acidic medium gives 2-(5-nitrofuran-2-ylmethyl)isoquinolin-1-one, whereas weaker acidic conditions lead to dinitration. Curtius rearrangement of 3-carboranylbutanoyl azide and trapping with 5-nitrofuran-2-ylmethanol gives 5-nitrofuran-2-ylmethyl N-(3-carboranylpropyl)carbamate. Biomimetic reduction of these nitrofuranylmethyl derivatives of anticancer drugs triggers release of the parent drugs. Thus, these nitrofurans have potential applications as pro-drugs for selective release of therapeutic drugs in hypoxic solid tumours.